Amicus Therapeutics, Inc.FOLDNASDAQ
LOADING
|||
Key Metrics
As of 2024• vs 2023
Per Share
Revenue/Share
$1.74+28.3%
Net Income/Share
$-0.18+64.1%
Operating CF/Share
$-0.11+52.4%
Free CF/Share
$-0.12+52.6%
Cash/Share
$0.82-15.3%
Book Value/Share
$0.64+17.5%
Tangible Book/Share
$-0.07+65.0%
Equity/Share
$0.64+17.5%
Interest Debt/Share
$1.62-3.4%
Valuation
Market Cap
$2.87B-31.5%
Enterprise Value
P/E Ratio$3.10B-29.4%
-51.10-85.0%
P/S Ratio5.43-48.3%
P/OCF Ratio
-84.60-39.6%
P/FCF Ratio
P/B Ratio-76.57-39.9%
14.78-43.5%
P/TB Ratio
EV/Sales14.78-43.5%
5.86-46.6%
EV/EBITDA
105.38+321.2%
Profitability
Earnings Yield-1.96%+45.9%
FCF Yield-1.31%+28.5%
ROE-28.91%+69.4%
ROIC3.86%+130.9%
Return on Tangible Assets-9.84%+63.7%
Capital Allocation
CapEx/OCF
-10.48%+2.6%
CapEx/Revenue
0.67%-63.9%
CapEx/Depreciation
0.42-56.0%
SBC/Revenue
16.07%-25.4%
Balance Sheet
Debt/Equity2.29-17.7%
Debt/Assets0.57-1.2%
Net Debt/EBITDA
Current Ratio7.82+463.7%
3.39+17.8%
Interest Coverage0.50x+132.6%
Income Quality0.60+32.5%
Efficiency
Days Sales Outstanding
70 days-12.8%
Days Payables Outstanding
89 days-39.6%
Days Inventory
819 days+40.3%
Receivables Turnover
5.23x+14.7%
Payables Turnover
4.09x+65.6%
Inventory Turnover
0.45x-28.7%
Special Valuations
Graham Number
--
Graham Net-Net
$-0.68+15.4%